KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Interest & Investment Income (2016 - 2025)

Historic Interest & Investment Income for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $8.2 million.

  • Acadia Pharmaceuticals' Interest & Investment Income rose 2520.5% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.4 million, marking a year-over-year increase of 3096.51%. This contributed to the annual value of $25.5 million for FY2024, which is 4771.96% up from last year.
  • According to the latest figures from Q3 2025, Acadia Pharmaceuticals' Interest & Investment Income is $8.2 million, which was up 2520.5% from $7.2 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Interest & Investment Income ranged from a high of $8.2 million in Q3 2025 and a low of $105000.0 during Q1 2022
  • Its 5-year average for Interest & Investment Income is $3.9 million, with a median of $4.1 million in 2023.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Interest & Investment Income plummeted by 9330.88% in 2021, and later soared by 351904.76% in 2023.
  • Over the past 5 years, Acadia Pharmaceuticals' Interest & Investment Income (Quarter) stood at $129000.0 in 2021, then soared by 2713.95% to $3.6 million in 2022, then skyrocketed by 31.1% to $4.8 million in 2023, then skyrocketed by 47.24% to $7.0 million in 2024, then increased by 17.68% to $8.2 million in 2025.
  • Its last three reported values are $8.2 million in Q3 2025, $7.2 million for Q2 2025, and $7.9 million during Q1 2025.